BioNexus Gene Lab Corp
BGLCBuild a strategy around BGLC
BioNexus Gene Lab Corp AI Insights
Informational only. Not investment advice.Snapshot
- Burning 2.8M FCF TTM on 9.5M revenue (-29% FCF margin) with only 1.2M cash remaining - ~5 months runway at current burn rate[Free Cash Flow TTM]
- Asset turnover 1.02x vs industry median 0.20x - 5x more capital efficient, but efficiency meaningless without profitability[Asset Turnover TTM]
- Trading at 0.56x book value with 6.8M equity and minimal debt (0.03 D/E) - deep discount if turnaround succeeds[P/B Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 500K or financing announced — Signals imminent dilution event or going concern risk
- Gross Margin TTM: Improves above 25% — First sign cost structure can support eventual profitability
- Total Revenue TTM: Quarterly revenue inflects positive YoY — Revenue decline reversing would extend runway and improve financing terms
Bull Case
Deep value at 0.56x book with 6.8M tangible equity, zero goodwill risk, and 0.03 D/E - acquirer pays 57 cents per dollar of assets
5x industry asset turnover (1.02x vs 0.20x median) shows operational efficiency - path to profitability if gross margin improves from 15%
Bear Case
5-month cash runway with -2.8M FCF burn and no clear path to profitability - dilution or bankruptcy imminent
Gross margin 15% vs industry median 54% - structurally uncompetitive cost structure unlikely to support turnaround
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage BGLC's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway crisis will force dilutive financing or strategic sale within 12 months
- 1.2M cash vs 2.8M annual burn = ~5 month runway
- Revenue declining 4% 3Y CAGR while losses persist
- No debt capacity with current losses
Valuation Context
Caveats
Public Strategies Rankings
See how BioNexus Gene Lab Corp ranks across different investment strategies.
Leverage BGLC's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
BGLC Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$3.97M | — | ||
$3.0M | — | ||
0.00 | — | ||
$9.47M | +2.2% | — | |
$-1.28 | — | ||
-26.9% | -17.2% | — | |
-24.3% | -14.1% | — | |
$-2.76M | — | ||
-28.4% | -18.5% | — | |
Beta 5Y (Monthly) | unknown | — |
BGLC Dividend History
BGLC Stock Splits
BGLC SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/14/25 | 09/30/25 | 10-Q | |
08/18/25 | 06/30/25 | 10-Q | |
05/15/25 | 03/31/25 | 10-Q | |
04/15/25 | 12/31/24 | Unknown | |
11/15/24 | 09/30/24 | 10-Q | |
08/14/24 | 06/30/24 | 10-Q | |
05/15/24 | 03/31/24 | 10-Q | |
04/16/24 | 12/31/23 | 10-K | |
11/20/23 | 09/30/23 | 10-Q | |
08/16/23 | 06/30/23 | 10-Q | |
05/09/23 | 03/31/23 | 10-Q | |
03/31/23 | 12/31/22 | 10-K | |
03/26/24 | 09/30/22 | 10-Q/A | |
11/14/22 | 09/30/22 | 10-Q | |
08/15/22 | 06/30/22 | 10-Q | |
05/16/22 | 03/31/22 | 10-Q | |
04/06/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/12/21 | 06/30/21 | 10-Q | |
05/18/21 | 03/31/21 | 10-Q | |
03/30/21 | 12/31/20 | 10-K | |
11/03/20 | 09/30/20 | 10-Q | |
08/11/20 | 06/30/20 | 10-Q | |
05/08/20 | 03/31/20 | 10-Q | |
03/31/20 | 12/31/19 | 10-K | |
11/03/20 | 09/30/19 | 10-Q | |
08/11/20 | 06/30/19 | 10-Q | |
05/08/20 | 03/31/19 | 10-Q |